A number of investment brokers have recently updated their price targets on shares of Argos Therapeutics Inc (ARGS). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/19/2016 – Argos Therapeutics Inc had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 18 price target on the stock.

03/30/2016 – Argos Therapeutics Inc had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 10 price target on the stock.

03/17/2016 – Argos Therapeutics Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 14 price target on the stock.

03/08/2016 – Argos Therapeutics Inc had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 11 price target on the stock.

03/07/2016 – Argos Therapeutics Inc had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 11 price target on the stock.

06/09/2015 – Argos Therapeutics Inc had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 13 price target on the stock.

05/01/2015 – Argos Therapeutics Inc had its “sell” rating reiterated by analysts at Zacks.

The share price of Argos Therapeutics Inc (ARGS) was up +13.59% during the last day of trading, with a day high of 5.94. 895486 shares were traded during the last session.

The stock’s 50 day moving average is 7.14 and its 200 day moving average is 4.63. The stock’s market capitalization is 121.30M. Argos Therapeutics Inc has a 52-week low of 1.61 and a 52-week high of 13.97.

View other investors thoughts on Argos Therapeutics Inc with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.